{
  "docId": "019de075-dd1e-7468-9323-d12fde1b7732",
  "docSlug": "a9cc0c508d45d8985f57408ace49b969",
  "documentTitle": "RayzeBio | IPO Presentation Deck | 41 slides",
  "authorId": "rayzebio",
  "authorName": "RayzeBio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 16,
  "pageCount": 41,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a process-oriented layout to show the transition between trial phases.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/16",
  "deckHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732",
  "deckJsonHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json",
  "deckAnchorHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.03,
        "y": 0.45
      },
      "kind": "list",
      "text": "Phase 1b: Dose de-escalation trial: 17 patients enrolled. Initial and only cohort studied at Phase 3 dose. Assessed DLTs 8 weeks after 1st cycle; No DLTs observed. Primary endpoint is safety. US study. Status: All patients completed dosing; follow-up ongoing",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7bbb599c-aa36-4106-a582-704635a1c50d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.52,
        "y": 0.18
      },
      "kind": "list",
      "text": "Key Eligibility Criteria: Progressive disease following treatment with 177Lu SSA (e.g. Lutathera); Age >= 18; Well-differentiated GI-NETs and P-NETs with positive SSTR-PET imaging",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a16d4a76-3e82-4e78-8d6d-446f51ba5d06",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.52,
        "y": 0.45
      },
      "kind": "list",
      "text": "Phase 3: Pivotal trial: Randomized clinical trial of RYZ101 against standard of care (high dose SSA, everolimus, sunitinib). Primary endpoint of progression free survival. Global study. Status: Enrolling now",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e53bd7b0-6fa6-4bf3-9430-12744da6acc3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.09,
        "y": 0.34
      },
      "kind": "paragraph",
      "text": "ACTINium fOr Neuroendocrine tumors",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96f21ea2-6000-46ac-993f-88ceb403fd66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "RYZ101 ACTION-1 Trial: Streamlined Phase 1b to Phase 3 Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d401de6b-36ef-412e-be06-420a0f8559d6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 15,
      "beatId": "a134e4cc-5c5e-4ea7-8bd8-6d4ed3346f90",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents RYZ101 as a solution to the unmet need in NETs, highlighting its promising characteristics and clinical trial results.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 16,
      "name": "Hypothesis Test",
      "slug": "42-hypothesis-test",
      "bestFor": "Strategy validation, due diligence, research presentations",
      "matchId": "dd065b7b-77b8-4f37-837e-80ec7e755de5",
      "evidence": "The document presents clinical trial results for RYZ101, including Phase 1b preliminary response analysis and efficacy data.",
      "position": 2,
      "objective": "How does RYZ101 perform in clinical trials?",
      "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
      "confidence": 0.7,
      "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}